What evidence guides the optimal timing of delivery for a growth‑restricted fetus with an absent or reversed a‑wave in the ductus venosus?

Delivery Timing for FGR with Absent or Reversed Ductus Venosus A-Wave

For fetal growth restriction with absent or reversed a-wave in the ductus venosus before 32 weeks, delivery timing should be guided by computerized cardiotocography (cCTG) and ductus venosus Doppler changes, with delivery typically occurring between 30-32 weeks of gestation, as this approach has demonstrated the best neurodevelopmental outcomes at 2 years (95% without impairment) compared to other monitoring strategies. 1

Evidence-Based Delivery Timing Algorithm

Before 32 Weeks of Gestation (Early-Onset FGR)

When absent or reversed ductus venosus a-wave is detected:

• Immediate actions: Hospitalize the patient, administer antenatal corticosteroids, and initiate intensive surveillance with cardiotocography at least 1-2 times daily 2
• Delivery decision: Base timing on the entire clinical picture including cCTG short-term variation and ductus venosus findings 1
• Optimal approach: The TRUFFLE trial demonstrated that waiting for "late" ductus venosus changes (a-wave at or below baseline) combined with cCTG safety net monitoring resulted in 95% of infants being neurologically intact at 2 years, compared to 85% with cCTG-based timing alone 1

At 32-34 Weeks of Gestation

The management diverges between guidelines:

• RCOG (2024) approach: Consider delivery from 30 weeks when umbilical artery shows reversed end-diastolic flow, and from 32 weeks when absent end-diastolic flow is present. Continue monitoring with ductus venosus and cCTG if delaying to later gestations 1
• SMFM (2020) approach: Recommend delivery at 30-32 weeks for reversed umbilical artery end-diastolic velocity, though they suggest ductus venosus Doppler should not be used for routine clinical management 2

Critical Nuances and Divergent Evidence

The SMFM-RCOG Divergence

There is a fundamental disagreement between major guidelines regarding ductus venosus use:

• SMFM (2020) explicitly recommends against routine ductus venosus Doppler for clinical management (GRADE 2B) 2
• RCOG (2024) strongly endorses ductus venosus monitoring based on TRUFFLE trial outcomes, showing superior neurodevelopmental results 1

This divergence reflects different interpretations of the same evidence. The TRUFFLE study showed improved 2-year neurodevelopmental outcomes with ductus venosus-guided delivery, but this came with a non-significant trend toward increased perinatal mortality (8% overall perinatal death rate) 1.

Risk Stratification by Ductus Venosus Findings

The severity of ductus venosus abnormality matters significantly:

• Absent a-wave: Associated with 11-fold increased odds of stillbirth (OR 11.16,95% CI 6.31-19.73), with 20% frequency of stillbirth 2, 3
• Reversed a-wave: Carries 46% risk of stillbirth in severe cases 2
• Recent data (2026): All observed fetal deaths showed either reversed umbilical artery end-diastolic flow OR abnormal ductus venosus Doppler at the examination preceding death 4

Practical Management Approach

Surveillance Intensity

When absent or reversed ductus venosus a-wave is present:

• Doppler assessment: 2-3 times per week for umbilical artery 2
• Cardiotocography: At least 1-2 times daily 2
• Hospital admission: Strongly consider for surveillance frequency exceeding 3 times per week 2

Delivery Decision Framework

Prioritize delivery when:

1. Reversed a-wave in ductus venosus is detected (highest risk)
2. Gestational age reaches 30-32 weeks with persistent abnormalities
3. cCTG shows concerning short-term variation below safety thresholds
4. Any additional signs of fetal decompensation appear

Consider expectant management only if:

• Gestational age <30 weeks
• cCTG remains reassuring
• Only absent (not reversed) a-wave present
• Intensive monitoring feasible

Essential Adjunctive Interventions

• Antenatal corticosteroids: Mandatory if delivery anticipated before 34 weeks (GRADE 1A) 2
• Magnesium sulfate: For neuroprotection if <32 weeks (GRADE 1A) 2
• Mode of delivery: Consider cesarean delivery based on the entire clinical scenario, given high risk of intrapartum compromise 2

Common Pitfalls to Avoid

1. Delaying delivery beyond 32 weeks when reversed ductus venosus a-wave is present—the risk of fetal death escalates dramatically
2. Relying solely on umbilical artery Doppler without ductus venosus assessment in early-onset FGR—this misses critical cardiac compromise indicators
3. Using visual CTG interpretation alone rather than computerized analysis—the TRUFFLE trial specifically used cCTG with objective short-term variation measurement
4. Assuming all absent/reversed a-waves are equivalent—reversed carries substantially higher mortality risk than absent

The Bottom Line for Clinical Practice

Despite SMFM's recommendation against routine ductus venosus use, the most recent (2024) RCOG guideline and the landmark TRUFFLE trial data support its use specifically in early-onset FGR before 32 weeks. The 10% absolute improvement in neurodevelopmental outcomes (85% vs 95% intact survival) represents a clinically meaningful benefit that justifies ductus venosus monitoring in this high-risk population 1. The key is using it in conjunction with cCTG, not in isolation, and understanding that absent or reversed a-wave signals advanced fetal compromise requiring either immediate delivery or extremely intensive monitoring with low threshold for intervention.